Quality Appraisal of Nutritional Guidelines to Prevent, Diagnose, and Treat Malnutrition in All Its Forms during Pregnancy.

This work aimed to identify clinical practice guidelines (CPGs) that include recommendations for the prevention, diagnosis, and treatment of women's malnutrition during pregnancy and to evaluate the quality of these guidelines using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument. We conducted a literature review using PubMed and different websites from January 2009 to February 2021. The quality of the CPGs was independently assessed by reviewers using the AGREE II instrument, which defines guidelines scoring >70% in the overall assessment as "high quality". The analysis included 43 guidelines. Among the main findings, we identified that only half of the CPGs (51.1%) obtained a final "high quality" evaluation. AGREE II results varied widely across domains and categories. The two domains that obtained the highest scores were scope and purpose with 88.3% (range 39 to 100%) and clarity of presentation with 87.2% (range 25 to 100%). Among the "high quality" CPGs, the best scores were achieved by the three guidelines published by the National Institute of Health and Care Excellence (NICE) and the World Health Organization (WHO). Due to the importance of maternal nutrition in pregnancy, it is essential to join forces to improve the quality of the guidelines, especially in CPGs that do not meet the reference standards for quality.

Multiprofessional care promotes of quality of life in pregnant women with preeclampsia: a cross-sectional study

OBJECTIVES: To assess the quality of life of hospitalized pregnant women with preeclampsia (PE), and compare with a group of healthy pregnant women (HP). METHODS: This was an observational cross-sectional study conducted among 58 pregnant women; 28 of them had preeclampsia and 30 were healthy. The WHOQOL-Bref questionnaire, which was divided into four aspects: physical, psychological, social, and environmental, was applied to each subject. RESULTS: A statistically significant difference was observed regarding maternal age (PE 27.8±6.2 x HG 23.0±6.6, p<0.01) and gestational age (PE 224±28.1 x HG 253.8±43.7, p<0.01) in relation to the clinical and obstetric data. No significant difference was observed among groups in the physical (PE 57.7±18.9 x HG 65.7±16.6, p=0.19), psychological (PE 68.2±12.8 x HG 73.3±13.30, p=0.16), social (PE 72.0±15.8 x HG 71.7±18.7, p=0.78), or environmental (PE 61.1±11.9 x HG 59.3±15.9, p=0.88) aspects of the WHOQOL-Bref. CONCLUSIONS There was no difference in quality of life between the groups studied, a result possibly due to the fact that women with PE were hospitalized and received multiprofessional care.

Reference intervals for hemoglobin A1c (HbA1c) in healthy Mexican pregnant women: a cross-sectional study.

BACKGROUND: The reference intervals for hemoglobin A1c (HbA1c) in pregnant Mexican women without diabetes are not well defined. The study aims to determine the reference intervals for HbA1c at each trimester in healthy Mexican pregnant women. METHODS: This cross-sectional study included healthy Mexican pregnant women in trimester 1 (T1), 6-13.6 weeks of gestation (WG), trimester 2 (T2), 14-27 WG, and trimester 3 (T3), ≥27-36 WG, with a maternal age > 18 years, and pregestational body mass index (BMI) ranging between 18.5-24.9 kg/m2. Women with gestational diabetes mellitus, pregestational diabetes, anemia, a pregestational BMI < 18.5 or ≥ 25 kg/m2, and any hematologic, hepatic, immunological, renal, or cardiac disease were excluded. HbA1c was measured using high-performance liquid chromatography based on the National Glycohemoglobin Standardization Program-certified PDQ Primus guidelines. The HbA1c reference intervals were calculated in terms of the 2.5th to the 97.5th percentiles. RESULTS: We analyzed the HbA1c values of 725 women (T1 n = 84, T2 n = 448, and T3 n = 193). The characteristics of the participants were expressed as mean ± standard deviation and included: maternal age (28.2 ± 6.7 years), pregestational weight (54.8 ± 5.9 Kg), pregestational BMI (22.2 ± 1.7 Kg/m2), and glucose values using a 75 g-2 h oral glucose tolerance test; fasting 4.5 ± 0.3 mmol/L (81.5 ± 5.5 mg/dL), 1 h 6.4 ± 1.5 mmol/L (115.3 ± 26.6 mg/dL), and 2 h 5.7 ± 1.1 mmol/L (103.5 ± 19.6 mg/dL). Reference intervals for HbA1c, expressed as median and 2.5th to 97.5th percentile for each trimester were: T1: 5.1 (4.5-5.6%), T2: 5.0 (4.4-5.5%), and T3: 5.1 (4.5-5.6%). CONCLUSIONS: The reference range of HbA1C in healthy Mexican pregnant women during pregnancy was 4.4% to 5.6%. We suggest as upper limits of HbA1c value ≤5.6%, 5.5%, and 5.7% for T1, T2, and T3, respectively among Mexican pregnant women.

Diagnóstico, Evaluación y Manejo de la Enfermedad Renal en el Embarazo / Diagnosis, Evaluation, and Management of renal diseases during Pregnancy

Introducción: La elevada prevalencia de enfermedad renal crónica y otras enfermedades no transmisibles crónicas, unido al incremento en la edad de embarazo ha generado nuevas investigaciones y evidencias de la relación entre la enfermedad renal crónica, el embarazo y los resultados para la madre y el feto. Objetivo: Exponer las mejores prácticas actuales y ofrece una aproximación al diagnóstico, evaluación y tratamiento de la enfermedad renal en el contexto del embarazo y su repercusión en términos de morbilidad y mortalidad para la madre y el feto. Material y Métodos: Se realizó un análisis de la literatura describiendo los mejores resultados clínicos basado en los avances científicos a la fecha actual. Resultados: Se enfatiza la evolución continua entre el daño renal agudo (incipiente) y la falla renal aguda (con necesidad de métodos dialíticos sustitutivos), también de importancia pronóstica con incrementos en la mortalidad materna asociados a pequeños incrementos en la creatinina sérica. Conclusiones: Tanto el desarrollo de un daño renal agudo, la falla renal aguda y la enfermedad renal crónica son causas importantes de morbilidad y mortalidad materno fetal(AU)

Introduction: The high prevalence of chronic kidney disease and others non contagiables diseases, jointly with its increasing frequency in gestational age women have generated new investigations and evidences of the relationship between the chronic renal diseases, the pregnancy and its consequence for the mother and fetus. Objective: This paper summarizes the best practice up to this date and provides a reasonable approach to the diagnosis, evaluation, and treatment of the Renal Disease Disorders of Pregnancy to evaluate the impact of them on maternal and fetal morbidity and mortality. Material and Methods: An analysis of the published literature of the subject was performed, describing the best clinical results based on scientific advances available today. Results: Was emphasized the continuum evolution between acute kidney damage (incipient injury) and acute kidney failure (need to dialysis) also of importance for prognosis, with increasing of the mortality associated with small increases in serum creatinine. Conclusions: The acute kidney diseases/ acute renal failure and chronic renal diseases are important causes of maternal and perinatal morbidity - mortality(AU)